DOD Reconstructive Transplant, Idea Discovery Award | HT9425 23 RTRP IDA

FAQs: FY23 DoD Reconstructive Transplant Research Program (RTRP) Idea Discovery Award

What is this funding opportunity?

The FY23 Department of Defense (DoD) Reconstructive Transplant Research Program (RTRP) Idea Discovery Award is a discretionary research funding opportunity administered through the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). The Funding Opportunity Number is HT9425 23 RTRP IDA.

What is the main purpose of the Idea Discovery Award?

This mechanism is designed to support early, exploratory research in reconstructive transplant, with a preference for ideas that are genuinely new, not yet proven, and somewhat risky. The goal is to generate solid, convincing proof-of-concept data that can justify and enable larger follow-on studies, rather than delivering a fully translated solution in a single award period.

What kinds of projects are considered a good fit?

Projects are a good fit when they introduce innovative concepts, theories, paradigms, or methods that open new directions in reconstructive transplant or vascularized composite allotransplantation (VCA). The strongest fit is research that challenges existing assumptions or approaches a persistent problem from an unfamiliar angle, while still presenting a clear, testable hypothesis and a scientifically defensible plan to produce interpretable results.

How does the program define "innovation" for this award?

Innovation is central. Applications are expected to propose something meaningfully new, such as a novel concept, a new way of thinking, a paradigm shift, or a method that changes how the field might approach a problem. The program states that incremental studies will not be funded under this award.

What does "incremental studies will not be funded" mean in practice?

It means proposals that mainly extend prior published work, add another experimental condition, or represent the next logical step in an ongoing research line are unlikely to be considered responsive. The award is intended for new directions, not straightforward continuations.

Can an application build on solid organ transplant research?

Yes, but if established findings from solid organ transplant research are used, the application must clearly explain what is novel in reconstructive transplant or VCA and why the VCA setting could produce different outcomes, require confirmation, or offer unique mechanistic insight.

Is a hypothesis required even though the work is exploratory?

Yes. Proposals should include a testable hypothesis, a coherent rationale, and a strong study design. The mechanism supports untested and exploratory ideas, but it still expects a well-formed scientific argument and a plan that can generate interpretable data.

Are preliminary or published data required?

Yes. Even though the research is intended to be early-stage and exploratory, preliminary or published data are still required to justify the premise and demonstrate feasibility. The idea can be bold and unproven, but the application must show enough grounding that reviewers can be confident the work can be executed.

What is meant by "impact" for this opportunity?

Impact is a central review priority and is framed around what the project will produce in the near term and how those outputs could enable longer-term gains. Applicants are expected to describe concrete deliverables and explain how those deliverables could shape future directions in reconstructive transplant research or practice.

Does the project need to align with specific focus areas?

Yes. Projects must address at least one of the FY23 RTRP Idea Discovery Award Focus Areas. The specific focus areas are not listed in the provided summary, but alignment with at least one is explicitly required.

What types of deliverables does the program expect?

Applicants are expected to specify what the work will produce, such as:

• Knowledge products (for example, mechanistic insight, proof-of-concept evidence, or a validated method)
• Material products (such as a tool, assay, platform, or dataset)

The application should also describe how these near-term products could translate into longer-term benefits for the field.

Is military relevance required?

Yes. Military relevance is required. The research must be clearly tied to the health care needs of Service Members and/or Veterans recovering from traumatic injury. The opportunity also recognizes potential benefits to family members, caregivers, and clinicians, as well as to the general public, but the link to military health needs must be clear.

Is collaboration with military researchers or clinicians required?

No. Collaboration is encouraged but not mandatory. However, working with military researchers and clinicians can help demonstrate alignment with real-world needs in military medicine and rehabilitation.

Are clinical trials allowed under this award?

No. Clinical trials are not allowed. The opportunity uses the standard definition of a clinical trial: any study in which one or more human subjects are prospectively assigned to one or more interventions (including placebo or controls) to evaluate effects on biomedical or behavioral health-related outcomes.

What human subjects research is allowed, if any?

Human subjects research or work involving anatomical substances is generally not supported unless it qualifies for exemption under 32 CFR 219.104(d) or is eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. Studies that do not meet exempt or expedited criteria will be administratively withdrawn and will not be funded.

What does "administratively withdrawn" mean here?

It means the application will be removed from consideration during administrative review if it includes human subjects or anatomical substances research that does not qualify as exempt or expedited, or if it otherwise violates the stated human research limitations. An administratively withdrawn application is not reviewed for funding and cannot be selected for an award under this mechanism.

What research approaches are most compatible with these human research limitations?

Because clinical trials are prohibited and non-exempt/non-expedited human research leads to withdrawal, the mechanism effectively pushes applicants toward preclinical, in vitro, computational, or other non-clinical approaches that can still produce strong foundational and proof-of-concept data.

Who is eligible to apply?

The opportunity indicates an unrestricted applicant pool, meaning broad eligibility across entity types, subject to any additional eligibility clarifications that may appear in the full announcement.

What type of funding instrument will be used?

Awards may be made as grants or cooperative agreements.

What is the CFDA number for this program?

The CFDA number listed is 12.420.

When was this opportunity posted and when did it close?

The opportunity was created on June 5, 2023, and the original closing date shown is October 11, 2023.

How many awards are expected?

The listing indicates an expected five awards.

What is the maximum award amount (award ceiling)?

The published award ceiling in the summarized record is shown as 0. In this context, that typically indicates a specific maximum dollar amount was not provided in the summary record and would need to be confirmed in the full funding announcement or associated program documentation.

What should applicants emphasize to stay aligned with the award intent?

Based on the provided description, applicants should emphasize: a genuinely novel and non-incremental idea; a testable hypothesis; a strong rationale and study design; preliminary or published data supporting feasibility; a clear link to at least one FY23 RTRP focus area; a strong military relevance narrative; concrete near-term outputs; and compliance with restrictions on human subjects research and the prohibition on clinical trials.